ICU

SeaStar Medical Holding Corp

4 filings tracked

healthcarebiotechnologyMICRO (<$300M)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

bearishMay 13

Net loss of $3.5 million continues despite revenue growth.

earnings miss

70%

bullishMay 13

Gross margins reached approximately 91% due to low cost of goods sold.

margin expansion

90%

neutralMay 13

Utilization of SEPA and ATM offerings to maintain dwindling cash reserves.

capital raise

50%

bullishMay 13

Six FDA Breakthrough Device Designations accelerate adult SCD pathway.

regulatory action

80%

bearishMay 13

Operating expenses surged 45% while revenue grew only 2%.

margin compression

70%

bearishMay 13

Long-term debt facility increased to $50 million amid falling cash reserves.

debt restructure

60%

bearishMay 13

Warrants are significantly out-of-the-money, increasing the risk of future equity restructuring.

dilution risk

50%

bearishMay 13

Net loss of $3.5 million continues despite revenue growth.

earnings miss

70%

bullishMay 13

Gross margins reached approximately 91% due to low cost of goods sold.

margin expansion

90%

neutralMay 13

Utilization of SEPA and ATM offerings to maintain dwindling cash reserves.

capital raise

50%

bullishMay 13

Six FDA Breakthrough Device Designations accelerate adult SCD pathway.

regulatory action

80%

bearishMay 13

Operating expenses surged 45% while revenue grew only 2%.

margin compression

70%

bearishMay 13

Long-term debt facility increased to $50 million amid falling cash reserves.

debt restructure

60%

bearishMay 13

Warrants are significantly out-of-the-money, increasing the risk of future equity restructuring.

dilution risk

50%

Filing History

10-QMay 13, 2026

The Q1 2026 filing highlights a company at a crossroads between technological validation and financial instability. On one hand, the rapid growth in revenue and the completion of the SAVE Surveillance Registry prove that the SCD technology works and has a market. On the other hand, the persistent operating losses and the 'going concern' qualification underscore the extreme risk associated with early-stage medical device commercialization. Investors are essentially betting on a 2027 catalyst. The ability of SeaStar to survive until the adult SCD results are released depends entirely on its ability to secure non-dilutive funding or successfully execute its SEPA. While the dismissal of the class action lawsuit is a positive step, the overarching story remains one of high-risk, high-reward, where the clinical potential of the device is currently fighting against a depleting cash reserve.

8-KMay 13, 2026

The May 13 filing places SeaStar Medical at a crossroads between commercial viability and financial instability. While the company presents the results as evidence of an inflection point toward growth, the stark reality of its balance sheet—characterized by rising debt and accelerating burn—creates a high-risk environment for shareholders. The market must now decide if the reported commercial traction is sufficient to offset the deteriorating cash runway and the potential for equity dilution.